Zobrazeno 1 - 10
of 39
pro vyhledávání: '"BORUT Cizman"'
Autor:
Heide A. Stirnadel-Farrant, Angelo Karaboyas, Borut Cizman, Brian A. Bieber, Lata Kler, Delyth Jones, Alexander R. Cobitz, Bruce M. Robinson
Publikováno v:
Kidney International Reports, Vol 4, Iss 6, Pp 864-872 (2019)
Introduction: Cardiovascular (CV) morbidity and mortality are excessively high among hemodialysis (HD) patients. Anemia is a common complication of chronic kidney disease (CKD) and a known risk factor for CV events. To understand the impact of the re
Externí odkaz:
https://doaj.org/article/87864e505ec240ba80546f280000f9ec
Autor:
Borut Cizman, Helen T. Smith, Rodrigo Refoios Camejo, Linda Casillas, Harjeet Dhillon, Fan Mu, Eric Wu, Jipan Xie, Peter Zuckerman, Daniel Coyne
Publikováno v:
Kidney Medicine, Vol 2, Iss 5, Pp 589-599.e1 (2020)
Rationale & Objective: Since the change in erythropoiesis-stimulating agent (ESA) labeling and bundling of dialysis services in the United States, few studies have addressed the clinical importance of ESA hyporesponsiveness and none have considered h
Externí odkaz:
https://doaj.org/article/3b7e1f73f36e435a918384d65e3df5f2
Publikováno v:
Kidney International Reports, Vol 3, Iss 4, Pp 841-850 (2018)
Introduction: Hyporesponsiveness to recombinant human erythropoietin (rhEPO) is a major problem affecting some patients with chronic kidney disease (CKD), predominantly those on hemodialysis (HD). Daprodustat (GSK1278863) is a hypoxia-inducible facto
Externí odkaz:
https://doaj.org/article/d52ce01df2734f54b89b9c72e96d04d5
Autor:
Heide A. Stirnadel-Farrant, Jiacong Luo, Lata Kler, Borut Cizman, Delyth Jones, Steven M. Brunelli, Alexander R. Cobitz
Publikováno v:
BMC Nephrology, Vol 19, Iss 1, Pp 1-11 (2018)
Abstract Background A combination of safety concerns and labeling changes impacted use of erythropoiesis-stimulating agents (ESAs) in renal anemia. Data regarding contemporary utilization in pre-dialysis chronic kidney disease (CKD) are lacking. Meth
Externí odkaz:
https://doaj.org/article/5804556e0b1444b3aa0c4dc29db12b46
Autor:
Robert Wermers, Rainard Fuhr, Dirk Schnabel, Terra Arnason, Alix Bensacon, Borut Cizman, Deborah Wenkert, Yves Sabbagh, Kurt Gunter
Publikováno v:
Endocrine Abstracts.
Autor:
Iain C. Macdougall, Amy Mewborn Meadowcroft, Allison Blackorby, BORUT Cizman, Alexander R Cobitz, Sergio Godoy, Vivekanand Jha, Kirsten L. Johansen, Gearoid McMahon, Gregorio T. Obrador, Muh Geot Wong, Ajay K. Singh
Publikováno v:
American Journal of Nephrology.
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) affects 10–15% of the chronic dialysis population. We explored baseline characteristics and predictors of ESA hyporesponsiveness in a global randomized cardiovascular outc
Autor:
Vlado Perkovic, Allison Blackorby, Borut Cizman, Kevin Carroll, Alexander R Cobitz, Rich Davies, Tara L DiMino, Vivekanand Jha, Kirsten L Johansen, Renato D Lopes, Lata Kler, Iain C Macdougall, John J V McMurray, Amy M Meadowcroft, Gregorio T Obrador, Scott Solomon, Lin Taft, Christoph Wanner, Sushrut S Waikar, David C Wheeler, Andrzej Wiecek, Ajay K Singh
Publikováno v:
Nephrology Dialysis Transplantation. 37:2157-2170
Background Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important. Methods The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (A
Autor:
Sagar Nigwekar, Shelsea St Hillien, Rituvanthikaa Seethapathy, Scott Krinsky, Jeanfranco Torcatti, Jennifer Howe, Sahir Kalim, Ignacio Portales-Castillo, Beza Mengesha, Wen Wen, Borut Cizman, Yves Sabbagh
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Calciphylaxis is a rare but devastating disorder predominantly affecting patients with end-stage kidney disease [1]. Patients with calciphylaxis present with painful ischemic skin lesions caused by microvascular occlusion secondar
Autor:
Christoph Wanner, Gregorio T. Obrador, Sushrut S. Waikar, Kevin Carroll, Iain C. Macdougall, Rich Davies, Borut Cizman, Scott D. Solomon, David C. Wheeler, Alexander R. Cobitz, Andrzej Wiecek, Vivekanand Jha, Kirsten L. Johansen, Lata Kler, Allison Blackorby, Vlado Perkovic, Ajay K. Singh, Renato D. Lopes, John J.V. McMurray, Amy Meadowcroft
Publikováno v:
Nephrology Dialysis Transplantation. 37:960-972
Background The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbep
Autor:
Ajay K. Singh, Borut Cizman, Kevin Carroll, John J. V. McMurray, Vlado Perkovic, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lopes, Iain C. Macdougall, Gregorio T. Obrador, Sushrut S. Waikar, Christoph Wanner, David C. Wheeler, Andrzej Wiecek, Nicole Stankus, Frank Strutz, Allison Blackorby, Alexander R. Cobitz, Amy M. Meadowcroft, Gitanjali Paul, Prerna Ranganathan, Sangeeta Sedani, Scott Solomon
Publikováno v:
JAMA internal medicine. 182(6)
Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) therapy. Few studies of anemia treatment in an incident dialysis (ID) population ha